Torizuka K, Uemura K, Toru M, Shinohara Y, Nishimura T, Yonekura Y, Nakagawara J, Matsuda H, Sakai F, Matsuda K, Fukuyama H, Morimoto K
Fukui Medical School, Japan.
Kaku Igaku. 1996 Mar;33(3):293-301.
Iomazenil (IMZ) is a partial inverse agonist of central-type benzodiazepine receptors (BZR) which binds specifically to BZR with high affinity. The safety and clinical effectiveness of 123I-IMZ SPECT in the diagnosis of brain diseases were evaluated in 655 patients with various brain diseases, such as epilepsy, cerebrovascular diseases, degenerative diseases and mental disorders relating to BZR. This was a Phase 3 study conducted as a multicenter trial at 52 collaborating institutions. There was no significant adverse reactions in the clinical symptoms or abnormal laboratory test values. The investigators judged 123I-IMZ SPECT to be effective in 95% of 638 analyzed cases. The injected dose did not correlate with the image quality or the clinical effectiveness of 123I-IMZ SPECT, suggesting that these items depend largely on the characteristics of the apparatus used, the disease or pathology of the patients, rather than the dose. We conclude that 123I-IMZ imaging is safe and provides effective information based on BZR binding which is useful in the diagnosis of various brain diseases.
碘美普尔（IMZ）是中枢型苯二氮䓬受体（BZR）的部分反向激动剂，它以高亲和力特异性结合BZR。对655例患有各种脑部疾病（如癫痫、脑血管疾病、退行性疾病以及与BZR相关的精神障碍）的患者，评估了123I-IMZ单光子发射计算机断层扫描（SPECT）在脑部疾病诊断中的安全性和临床有效性。这是一项在52个合作机构进行的多中心3期研究。临床症状或实验室检查值异常方面均无显著不良反应。在638例分析病例中，研究人员判定123I-IMZ SPECT在95%的病例中有效。注射剂量与123I-IMZ SPECT的图像质量或临床有效性无关，这表明这些指标很大程度上取决于所用设备的特性、患者的疾病或病理情况，而非剂量。我们得出结论，123I-IMZ成像安全，且基于BZR结合提供有效信息，对各种脑部疾病的诊断有用。
